Yossi Gross

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.